LAVA Therapeutics (LVTX) Price & Analysis

Compare

164 Followers

LVTX Stock Chart & Stats

$1.74

-$0.03(-2.78%)

At close: Jan 08 4:00 PM EST

$1.74

-$0.03(-2.78%)

Day’s Range― - ―

52-Week Range$0.85 - $2.00

Previous CloseN/A

Volume31.56K

Average Volume (3M)430.90K

Market Cap

$42.75M

Enterprise Value-$20.66M

Total Cash (Recent Filing)$49.66M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.33

Next Earnings

Mar 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.27

Shares Outstanding26,305,296

10 Day Avg. Volume419,635

30 Day Avg. Volume430,902

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)0.92

Price to Sales (P/S)2.13

P/FCF Ratio-1.30

Enterprise Value/Market Cap-0.48

Enterprise Value/Revenue-4.14

Enterprise Value/Gross Profit1.06

Enterprise Value/Ebitda0.94

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

AcquisitionXOMA to acquire LAVA in cash-and-CVR deal, offering a definitive agreement for shareholders.

Clinical ProgressProgress continues with LAVA-1266, a Gammabody targeting CD123 for acute myeloid leukemia and myelodysplastic syndrome.

Financial PerformanceThe company reported license revenue of $5M and a net loss of $0.14 per share, better than the consensus estimate of revenue of $2.5M and a net loss of 0.30 per share.

Bears Say

Clinical ChallengesThe company's sole remaining wholly-owned clinical asset, LAVA-1266, lacks supportive clinical data.

Earnings ReportFor 1Q25, the company reported no revenue and a net loss of $0.13 per share.

Workforce ReductionIn February, the company announced a workforce reduction of approximately 30% and initiated a strategic review.

LAVA Therapeutics News

Xoma announces closing of transactions to acquire Lava Therapeutics

XOMA Royalty (XOMA) completed its previously announced acquisition of all the outstanding common shares of LAVA Therapeutics (LVTX)...

22d ago

LVTX

XOMA

Lava Therapeutics announces intent to delist from Nasdaq

LAVA Therapeutics (LVTX) announced that 22,877,463 of LAVA’s common shares, representing approximately 87% of LAVA’s outstanding common shares,...

30d ago

LVTX

XOMA

LAVA Therapeutics Delists from Nasdaq and Changes Leadership

LAVA Therapeutics ( ($LVTX) ) just unveiled an update. LAVA Therapeutics announced that following the expiration of a...

22d ago

LVTX

LAVA Therapeutics to Delist from Nasdaq Amid Acquisition

LAVA Therapeutics ( ($LVTX) ) has issued an update. On November 13, 2025, LAVA Therapeutics announced its intention...

30d ago

LVTX

Is LVTX a Buy, Before Earnings?

Lava Therapeutics Nv (LVTX) is scheduled to report 3rd quarter earnings on 11/12/2025. Regarding Q3 estimates, Wall Street...

1M ago

LVTX

LAVA Therapeutics Approves Merger with New Topco B.V.

LAVA Therapeutics ( ($LVTX) ) has provided an update. On November 7, 2025, LAVA Therapeutics held an extraordinary...

1M ago

LVTX

LAVA Therapeutics Amends Share Purchase Agreement

LAVA Therapeutics ( ($LVTX) ) has provided an announcement. On October 17, 2025, LAVA Therapeutics N.V. and XOMA...

2M ago

LVTX

Xoma, Lava Therapeutics announce amendment to purchase agreement

XOMA Royalty Corporation (XOMA) and LAVA Therapeutics N.V. (LVTX) announced that they have reached an agreement to amend...

2M ago

LVTX

XOMA

LAVA Therapeutics Extends Tender Offer Deadline

The latest announcement is out from LAVA Therapeutics ( ($LVTX) ). On October 2, 2025, LAVA Therapeutics and...

2M ago

LVTX

Xoma extends offer to acquire Lava Therapeutics

Xoma (XOMA) and Lava Therapeutics (LVTX) announced the extension of the expiration of the tender offer to purchase...

2M ago

LVTX

XOMA

LAVA Therapeutics Postpones EGM for XOMA Deal

LAVA Therapeutics ( ($LVTX) ) has provided an announcement. On September 30, 2025, LAVA Therapeutics announced the cancellation...

2M ago

LVTX

Lava Therapeutics to move Extraordinary General Meeting to early November

LAVA Therapeutics (LVTX) has decided to cancel the Extraordinary General Meeting of Shareholders scheduled to occur on September...

2M ago

LVTX

XOMA

Lava Therapeutics Reports Q2 2025 Financial Results

Lava Therapeutics Nv ( ($LVTX) ) has released its Q2 earnings. Here is a breakdown of the information...

4M ago

LVTX

LAVA Therapeutics Announces Acquisition by XOMA Corporation

LAVA Therapeutics ( ($LVTX) ) has issued an announcement. On August 13, 2025, LAVA Therapeutics announced its acquisition...

4M ago

LVTX

LVTX FAQ

What was LAVA Therapeutics’s price range in the past 12 months?

LAVA Therapeutics lowest stock price was $0.85 and its highest was $2.00 in the past 12 months.

What is LAVA Therapeutics’s market cap?

LAVA Therapeutics’s market cap is $42.75M.

When is LAVA Therapeutics’s upcoming earnings report date?

LAVA Therapeutics’s upcoming earnings report date is Mar 19, 2026 which is in 96 days.

How were LAVA Therapeutics’s earnings last quarter?

LAVA Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.267 earnings per share for the quarter, missing the consensus estimate of -$0.245 by -$0.022.

Is LAVA Therapeutics overvalued?

According to Wall Street analysts LAVA Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does LAVA Therapeutics pay dividends?

LAVA Therapeutics does not currently pay dividends.

What is LAVA Therapeutics’s EPS estimate?

LAVA Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does LAVA Therapeutics have?

LAVA Therapeutics has 26,305,296 shares outstanding.

What happened to LAVA Therapeutics’s price movement after its last earnings report?

LAVA Therapeutics reported an EPS of -$0.267 in its last earnings report, missing expectations of -$0.245. Following the earnings report the stock price went down -0.621%.

Which hedge fund is a major shareholder of LAVA Therapeutics?

Currently, no hedge funds are holding shares in LVTX

LAVA Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-101.50%

Trailing 12-Months

Asset Growth

-34.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

LAVA Therapeutics

LAVA Therapeutics (LVTX) is a biotechnology company focused on developing innovative treatments for cancer through its proprietary Gammabody platform, which leverages the unique properties of gamma delta T cells. The company specializes in advancing bispecific antibody therapies designed to enhance the immune system's ability to target and destroy cancer cells. LAVA operates primarily in the biopharmaceutical sector, concentrating on oncology and immunotherapy.